Janux Therapeutics, Inc. (NASDAQ:JANX) Insider Sells $107,188.10 in Stock

Janux Therapeutics, Inc. (NASDAQ:JANX - Get Free Report) insider Andrew Hollman Meyer sold 3,334 shares of the stock in a transaction dated Monday, March 3rd. The stock was sold at an average price of $32.15, for a total value of $107,188.10. Following the transaction, the insider now directly owns 82,139 shares in the company, valued at approximately $2,640,768.85. The trade was a 3.90 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Andrew Hollman Meyer also recently made the following trade(s):

• On Monday, February 3rd, Andrew Hollman Meyer sold 3,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $42.29, for a total value of $140,994.86.
• On Thursday, January 2nd, Andrew Hollman Meyer sold 13,334 shares of Janux Therapeutics stock. The shares were sold at an average price of $54.88, for a total value of $731,769.92.

Janux Therapeutics Price Performance

Shares of NASDAQ JANX traded down $0.11 during midday trading on Friday, hitting $30.64. 653,704 shares of the company's stock were exchanged, compared to its average volume of 818,280. Janux Therapeutics, Inc. has a twelve month low of $29.63 and a twelve month high of $71.71. The company has a market cap of $1.81 billion, a PE ratio of -26.19 and a beta of 3.23. The firm's fifty day simple moving average is $41.27 and its 200-day simple moving average is $47.48.

Remove Ads

Janux Therapeutics (NASDAQ:JANX - Get Free Report) last released its quarterly earnings results on Thursday, February 27th. The company reported ($0.36) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.49) by $0.13. Janux Therapeutics had a negative return on equity of 10.47% and a negative net margin of 463.91%. Equities analysts anticipate that Janux Therapeutics, Inc. will post -1.38 EPS for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the company. Plato Investment Management Ltd grew its stake in Janux Therapeutics by 18.7% during the 3rd quarter. Plato Investment Management Ltd now owns 1,186 shares of the company's stock worth $54,000 after buying an additional 187 shares during the last quarter. Russell Investments Group Ltd. grew its stake in Janux Therapeutics by 77.7% during the 4th quarter. Russell Investments Group Ltd. now owns 1,011 shares of the company's stock worth $54,000 after buying an additional 442 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in Janux Therapeutics during the 4th quarter worth approximately $59,000. Mirae Asset Global Investments Co. Ltd. grew its stake in Janux Therapeutics by 21.9% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,887 shares of the company's stock worth $87,000 after buying an additional 339 shares during the last quarter. Finally, Avanza Fonder AB purchased a new position in shares of Janux Therapeutics in the 4th quarter valued at approximately $139,000. Hedge funds and other institutional investors own 75.39% of the company's stock.

Analyst Ratings Changes

JANX has been the topic of a number of analyst reports. HC Wainwright reaffirmed a "buy" rating and issued a $70.00 price target on shares of Janux Therapeutics in a research report on Monday, March 3rd. Lifesci Capital raised Janux Therapeutics to a "strong-buy" rating in a research report on Friday, December 27th. Wedbush reaffirmed an "outperform" rating and issued a $76.00 price target (up previously from $75.00) on shares of Janux Therapeutics in a research report on Friday, February 28th. BTIG Research increased their price target on Janux Therapeutics from $82.00 to $100.00 and gave the company a "buy" rating in a research report on Tuesday, December 3rd. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and issued a $200.00 price target on shares of Janux Therapeutics in a research report on Wednesday, December 11th. One research analyst has rated the stock with a hold rating, ten have assigned a buy rating and two have assigned a strong buy rating to the stock. According to data from MarketBeat.com, Janux Therapeutics currently has a consensus rating of "Buy" and a consensus target price of $88.00.

Janux Therapeutics Company Profile

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.